Shots:
- The CVMP has recommended Portela (relfovetmab) for alleviating osteoarthritis pain in cats, with an EC decision expected in Q4’25 & commercial launch planned for 2026
- Opinion was based on superior safety & efficacy in cats across trials, incl. cats with IRIS stage 1–3 kidney disease, & showed relieved osteoarthritis pain
- Portela is a long-acting anti-NGF mAb therapy for cats, designed to deliver up to 3mos. of osteoarthritis pain relief with a single injection
Ref: Zoetis | Image: Zoetis | Press Release
Related News:- Zoetis Launches AI Masses to Detect Skin and Lymph Lesions
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
